KalVista Pharmaceuticals Inc. (KALV) announced Friday now that the U.S. Food and Drug Administration has notified the company that it will not meet the PDUFA goal date for the New Drug Application (NDA) for sebetralstat, the company's investigational oral on-demand treatment for hereditary angioedema (HAE).
The FDA notified the company that the previously disclosed June 17, 2025 PDUFA goal date will not be met due to heavy workload and limited resources. The FDA indicated that it expects to deliver a decision within approximately four weeks.
The company noted that the FDA has not requested additional data or studies and has not raised any concerns regarding the safety, efficacy or approvability of sebetralstat.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.